Login to Your Account

In his 35 years at Pfizer Inc., including tenure as the New York-based pharma's director of R&D operations, Frank Sciavolino was immersed in the science side of the business and didn't necessarily see himself in the role of a CEO.
LSK Biopharma inked an exclusive license agreement with the University of Utah's Huntsman Cancer Institute (HCI) to develop and commercialize HCI-1401, an orally bioavailable, small-molecule, irreversible inhibitor of Bruton's tyrosine kinase (BTK). The new asset doubles the cancer pipeline for the Salt Lake City-based biotech, which earlier this year completed a phase I/II trial of its lead compound, apatinib mesylate (YN968D1), in solid tumors.
Winning orphan drug status for a second preclinical cancer therapy is "small but important progress" for Nanosmart Pharmaceuticals Inc., President James Smith told BioWorld Today.
More Newco News Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: